Literature DB >> 18090932

Wiskott-Aldrich syndrome is an important differential diagnosis in male infants with juvenile myelomonocytic leukemialike features.

Nobuhiro Watanabe1, Ayami Yoshimi, Yoshiro Kamachi, Takashi Kawabe, Hideki Muramatsu, Kimikazu Matsumoto, Atsushi Manabe, Seiji Kojima, Koji Kato.   

Abstract

A newborn presented with thrombocytopenia at birth and subsequently developed leukocytosis, monocytosis, and mild hepatomegaly. The bone marrow was normocellular with dysplasia and spontaneous granulocyte-monocyte colony formation was demonstrated. These findings fulfilled the diagnostic criteria of juvenile myelomonocytic leukemia. Then he developed atopic dermatitislike eczema, which led to the consideration of Wiskott-Aldrich syndrome (WAS). Lack of intracellular WASP expression and WASP gene mutation confirmed the diagnosis of WAS. After stem cell transplantation, he is alive in good condition with normal WASP expression. WAS should be considered as a differential diagnosis in male infants with juvenile myelomonocytic leukemialike features.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090932     DOI: 10.1097/MPH.0b013e3181580ec5

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.

Authors:  Hirozumi Sano; Ryoji Kobayashi; Daisuke Suzuki; Kazue Yasuda; Masanori Nakanishi; Tetsuro Nagashima; Masafumi Yamada; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2012-06-27       Impact factor: 2.490

Review 2.  Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.

Authors:  Christian Flotho
Journal:  Epigenetics       Date:  2019-03-08       Impact factor: 4.528

Review 3.  Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.

Authors:  Ayami Yoshimi; Seiji Kojima; Naoto Hirano
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.